Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000037833
JPRN-UMIN000037833
Recruiting
未知

All-Patient General Drug Use Surveillance of Rozlytrek Capsule - Advanced or recurrent solid tumors with NTRK gene fusions - - All-Patient General Drug Use Surveillance of Rozlytrek Capsule- Advanced or recurrent solid tumors with NTRK gene fusions

Chugai Pharmaceutical Co. Ltd.0 sites200 target enrollmentSeptember 4, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAdvanced or recurrent solid tumors with NTRK gene fusions

Overview

Phase
未知
Intervention
Not specified
Conditions
Advanced or recurrent solid tumors with NTRK gene fusions
Sponsor
Chugai Pharmaceutical Co. Ltd.
Enrollment
200
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 4, 2019
End Date
January 31, 2028
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Advanced or recurrent solid tumor patients with ROS1 gene fusions expected to receive Rozlytrek during the enrollment period

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
All-Patient General Drug Use Surveillance of Rozlytrek Capsule -ROS1 fusion gene-positive unresectable advanced or recurrent non-small cell lung cancerROS1 fusion gene-positive unresectable advanced or metastatic non-small cell lung cancer
JPRN-UMIN000039529Chugai Pharmaceutical Co. Ltd.200
Recruiting
Not Applicable
All-Patient General Drug Use Surveillance of Rozlytrek Capsule -ROS1 fusion gene-positive unresectable advanced or recurrent non-small cell lung cancer
JPRN-UMIN000046619Chugai Pharmaceutical Co. Ltd.200
Recruiting
Not Applicable
General Drug Use Surveillance (All Patient Surveillance) of ENSPRYNG Syringes for Subcutaneous Injection - Prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica)
JPRN-UMIN000041047Chugai Pharmaceutical Co. Ltd.330
Recruiting
Not Applicable
General Drug Use Surveillance of RONAPREVE injection set (casirivimab [genetical recombination] and imdevimab [genetical recombination])- SARS-CoV-2 infection or prevention of onset
JPRN-UMIN000044927Chugai Pharmaceutical Co. Ltd.770
Recruiting
Not Applicable
Special drug use-results surveillance <Patients with cold agglutinin disease>Cold agglutinin disease
JPRN-UMIN000049607sanofi K.K.100